生物可降解的聚合物自组装的纳米药物的结构和特征

doi:10.3969/j.issn.1006-7795.2017.01.026

摘要/Abstract

摘要： 由生物可降解的聚合物为载体的纳米药物（例如脂质体、微球和微囊）可能有较好的药动学和药效学性质。如果生物可降解聚合物能携带药物穿越生物屏障，显示疾病部位靶向性，生物可降解的聚合物为载体的纳米药物既可监测药物实时分布，又可帮助理解疾病发病和病理。特别在药物化学领域，生物可降解聚合物受到许多研究者关注。本文重点综述了生物可降解聚合物的纳米药物的组装过程、形貌和特征。为了帮助相关领域的读者理解生物可降解聚合物的组装过程和纳米体系的形貌，本文提供了29幅图。这些图使生物可降解聚合物的纳米体系的特征可视化。

关键词: 可生物降解的聚合物, 纳米药物, 纳米结构, 组装过程, 组装机制

Abstract: Major progress in the understanding of the onset and pathology of a series of diseases highlights the biodegradable polymers based nano-medicine having desirable pharmaceutical and pharmacological property, targeting disease site, crossing biological barriers, exhibiting multiple functions and monitoring real-time drug-distribution. These advantages of nano-medicines attract a great deal of research interests, and the polymeric biodegradable conjugates have been deeply emphasized by medicinal chemistry in particular. In this regard, the present review focuses on the assembling process and feature of biodegradable polymers based nano-medicines. To get insight into the assembling process of the biodegradable polymers and to visualize the feature of the formed nano-species we provided a number of figures.

Key words: biodegradable polymers, nano-medicine, nano-structure, assembly process, assembly mechanism

中图分类号:

赵明, 彭师奇. 生物可降解的聚合物自组装的纳米药物的结构和特征[J]. 首都医科大学学报, 2017, 38(1): 126-142.

Zhao Ming, Peng Shiqi. Structure and feature of nano-medicines assembled by biodegradable polymers[J]. Journal of Capital Medical University, 2017, 38(1): 126-142.

参考文献

[1] Ensign L M, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles:The gastrointestinal mucus barriers[J]. Adv Drug Deliv Rev, 2012, 64(6):557-570.
[2] Koo O M, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging:a concise review[J]. Nanomedicine, 2005, 1(3):193-212.
[3] Mathur A B, Gupta V. Silk fibroin-derived nanoparticles for biomedical applications[J]. Nanomedicine, 2010, 5(5):807-820.
[4] Kaminskas L M, Boyd J, Porter C J. Dendrimer pharmacokinetics:the effect of size, structure and surface characteristics on ADME properties[J]. Nanomedicine, 2014, 6(6):1063-1084.
[5] Gao W, Xiao Z, Radovic-Moreno A, et al. Progress in siRNA delivery using multifunctional nanoparticles[J]. Methods Mol Biol, 2010, 629:53-67.
[6] Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers[J]. Beilstein J Org Chem, 2012, 8(23):2091-2099.
[7] Tian L, Bae Y H. Cancer nanomedicines targeting tumor extracellular pH[J]. Colloids Surf B Biointerfaces, 2012, 99:116-126.
[8] Duncan R, Vicent M J. Polymer therapeutics-prospects for 21st century:The end of the beginning[J]. Adv Drug Deliv Rev, 2013, 65(1):60-70.
[9] Marin E, Briceno M I, Caballero-George C. Critical evaluation of biodegradable polymers used in nanodrugs[J]. Int J Nanomed, 2013, 8:3071-3090.
[10] Vakili M, Rafatullah M, Salamatinia B, et al. Application of chitosan and its derivatives as adsorbents for dye removal from water and wastewater:A review[J]. Carbohydr Polym, 2014,113:115-130.
[11] Yang Y, Wang S, Wang Y, et al. Advances in self-assembled chitosan nanomaterials for drug delivery[J]. Biotechnol Adv, 2014, 32(7):1301-1316.
[12] Elgadir M A, Uddin M S, Ferdosh S, et al. Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems:A review[J]. J Food Drug Anal, 2015, 23(4):619-629.
[13] Prabaharan M. Chitosan-based nanoparticles for tumor-targeted drug delivery[J]. Int J Biol Macromol, 2015, 72(5):1313-1322.
[14] Wang H, Xu M, Xiong M, et al. Reduction-responsive dithiomaleimide-based nanomedicine with high drug loading and FRET-indicated drug release[J]. Chem Commun:Camb, 2015, 51(23):4807-4810.
[15] Mei L, Zhang Z, Zhao L,et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs[J]. Adv Drug Deliv Rev, 2013, 65(6):880-890.
[16] Huang P, Cui C Y, Wang Y J, et al. Preparation and evaluation of a liposome of PEG and epirubicin[J]. Journal of Capital Medical University, 2015, 36(2):166-172.
[17] Azzopardi E A, Conlan R S, Whitaker I S. Polymer therapeutics in surgery:the next frontier[J]. J Interdiscip Nanomed, 2016, 1(2):19-29.
[18] Mura S, Bui D T, Couvreur P, et al. Lipid prodrug nanocarriers in cancer therapy[J]. J Control Release, 2015, 208:25-41.
[19] Fay F, Scott C J. Antibody-targeted nanoparticles for cancer therapy[J]. Immunotherapy, 2011, 3(3):381-394.
[20] Cheng Y, Zhao L, Li Y, et al. Design of biocompatible dendrimers for cancer diagnosis and therapy:current status and future perspectives[J]. Chem Soc Rev, 2011, 40(5):2673-2703.
[21] Macewan S R, Callahan D J, Chilkoti A. Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery[J]. Nanomedicine, 2010, 5(5):793-806.
[22] Kedar U, Phutane P, Shidhaye S, et al. Advances in polymeric micelles for drug delivery and tumor targeting[J]. Nanomed, 2010, 6(6):714-729.
[23] Prabhu R H, Patravale V B, Joshi M D. Polymeric nanoparticles for targeted treatment in oncology:current insights[J]. Int J Nanomed, 2015, 10(1):1001-1018.
[24] Friberg S, Nystrom A M. Nanomedicine:will it offer possibilities to overcome multiple drug resistance in cancer?[J]. J Biotechnol, 2016, 14(1):1-17.
[25] Agyare E, Kandimalla K. Delivery of Polymeric Nanoparticles to Target Vascular Diseases[J]. J Biomol Res Ther, 2014, 3(1):1-24.
[26] Rubinstein I, Weinberg G L. Nanomedicines for chronic non-infectious arthritis:the clinician 3s perspective[J]. Nanomedicine, 2012, 8(Suppl 1):77-82.
[27] Low S A, Kopecek J. Targeting polymer therapeutics to bone[J]. Adv Drug Deliv Rev, 2012, 64, 1189-1204.
[28] Topete A, Barbosa S, Taboada P. Intelligent micellar polymeric nanocarriers for therapeutics and diagnosis[J]. J Appl Polym Sci, 2015, 132(41):1-18.
[29] Movassaghian S, Merkel O M, Torchilin V P. Applications of Polymer Micelles for Imaging and Drug Delivery[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2015, 7(5):691-707.
[30] Ryvolova M, Chomoucka J, Drbohlavova J, et al. Modern Micro and Nanoparticle-Based Imaging Techniques[J]. Sensors Basel, 2012, 12:14792-14820.
[31] Georgieva J V, Hoekstra D, Zuhorn I S. Smuggling Drugs into the Brain:An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier[J]. Pharmaceutics, 2014, 6(4):557-583.
[32] van O, Tellingen, B. Yetkin-Arik, M C de Gooijer,et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment[J]. Drug Resist Updat, 2015, 19(10):1-12.
[33] Forde E, Devocelle M. Pro-Moieties of Antimicrobial Peptide Prodrugs[J]. Molecules, 2015, 20, 1210-1227.
[34] Ungaro F, d'Angelo I, Miro A, et al. Engineered PLGA nano-and micro-carriers for pulmonary delivery:challenges and promises[J]. J Pharm Pharmacol, 2012, 64, 1217-1235.
[35] Cho Y, Borgens R B. Polymer and nano-technology applications for repair and reconstruction of the central nervous system[J]. Exp Neurol, 2012, 233(1):126-144.
[36] Carballo-Molina O A, Velasco I. Hydrogels as scaffolds and delivery systems to enhance axonal regeneration after injuries[J]. Front Cell Neurosci, 2015, 9:1-12.
[37] Islam M A, Firdous J, Choi Y J, et al. Design and application of chitosan microspheres as oral and nasal vaccine carriers:an updated review[J]. Int J Nanomed, 2012, 7(7):6077-6093.
[38] Yatuv R, Robinson M, Dayan-Tarshish I, et al. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia[J]. Int J Nanomed, 2010, 5(655):581-591.
[39] Yoshitomi T, Nagasaki Y. Nitroxyl radical-containing nanoparticles for novel nanomedicine against oxidative stress injury[J]. Nanomedicine, 2011, 6(3):509-518.
[40] Mei L, Jiang Y, Feng S S. Star-shaped block polymers as a molecular biomaterial for nanomedicine development[J]. Nanomedicine, 2014, 9(1):9-12.
[41] Han S, Li M, Liu X, et al. Construction of amphiphilic copolymer nanoparticles based on gelatin as drug carriers for doxorubicin delivery[J]. Colloids Surf B Biointerfaces, 2013, 102(102c):833-841.
[42] Tan G R, Feng S S, Leong D T. The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLAeTPGS nanoparticles[J]. Biomaterials, 2014, 35(9):3044-3051.
[43] Alcala-Alcala S, Urban-Morlan Z, Aguilar-Rosas I, et al. A biodegradable polymeric system for peptide-protein delivery assembled with porous microspheres and nanoparticles, using an adsorption/infiltration process[J]. Int J Nanomed, 2013, 8(13):2141-1251.
[44] Zhang X, Dong Y, Zeng X, et al. The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment[J]. Biomaterials, 2014, 35(6):1932-1943.
[45] Yang J, Xie S X, Huang Y, et al. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice[J]. Nanomedicine:Lond, 2012, 7(9):1297-1309.
[46] Guo L, Zhang H, Wang F, et al. Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system[J]. Int J Nanomed, 2015, 10:4535-4547.
[47] Shieh M J, Hsu C Y, Huang L Y, et al. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells[J]. J Control Release, 2011, 152(3):418-425.
[48] Zhu H, Chen H, Zeng X, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance[J]. Biomaterials, 2014, 35(7):2391-2400.
[49] Gui L, Zhao M, Wang Y, et al. Synthesis, nano-features, ex vivo anti-platelet aggregation and in vivo antithrombotic activities of poly-a,b-DL-aspartyl-L-arginine[J]. Med Chem Comm, 2012, 3(1):102-108.
[50] Gui L, Zhao M, Wang Y, et al. Synthesis, nanofeatures, in vitro thrombus lysis activity and in vivo thrombolytic activity of poly-a,b-aspartyl-l-alanine[J]. Nanomedicine, 2010, 5(5):703-714.
[51] Chen S, Wang Y, Li S, et al. Poly-a,b-aspartyl-Arg-Gly-Asp-Phe:a novel polymeric nanomedicine[J]. Med Chem Comm, 2015, 6(1):182-186.
[52] Li L, Wu J, Zhao M, et al. Poly-α,β-DL-aspartyl-L-cysteine:A novel nanomaterial having a porous structure, special complexation capability for Pb(II), and selectivity of removing Pb(II)[J]. Chem Res Toxicol, 2012, 25(9):1948-1954.
[53] Zhang H, Wang Y, Zhao M, et al. Synthesis and in vivo lead detoxification evaluation of Poly-α,β-DLaspartyl-L-methionine[J]. Chem Res Toxicol, 2012, 25(2):471-477.
[54] Patil R, Portilla-Arias J, Ding H, et al. Cellular delivery of doxorubicin via pH-Controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-L-Malic Acid)[J]. Int J Mol Sci, 2012, 13(9):11681-11693.
[55] Chen G, Liu J, Yang Y, et al. Preparation of pH-sensitive nanoparticles of poly (methacrylic acid) (PMAA)/poly (vinyl pyrrolidone) (PVP) by ATRP-template miniemulsion polymerization in the aqueous solution[J]. Colloid Polym Sci, 2015, 293(7):2035-2044.
[56] Poh S, Lin J B, Panitch A. Release of anti-inflammatory peptides from thermosensitive nanoparticles with degradable cross-links suppresses pro-inflammatory cytokine production[J]. Biomacromolecules, 2015, 16(4):1191-1200.
[57] Asuman Bozk?r B D. Design and evaluation of hydrophobic Ion-pairing complexation of lysozyme with sodium dodecyl sulfate for improved encapsulation of hydrophilic peptides/proteins by lipid-polymer hybrid nanoparticles[J]. J Nanomed Nanotechnol, 2015, 6(1):259-264.
[58] Malathi S, Nandhakumar P, Pandiyan V, et al. Novel PLGA-based nanoparticles for the oral delivery of insulin[J]. Int J Nanomed, 2015, 10:2207-2218.
[59] Lewis D R, Kamisoglu K, York A W, et al. Polymer-Based Therapeutics:Nanoassemblies and Nanoparticles for management of atherosclerosis[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2011, 3(4):400-420.
[60] Scott D, Rohr J, BaeY. Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity[J]. Int J Nanomed, 2011, 6(6):2757-2767.
[61] Cho H, Kwon G S. Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical Imaging[J]. ACS Nano, 2011, 5(11):8721-8729.
[62] Gao X, Wang B, Wei X, et al. Preparation, characterization and application of star-shaped PCL/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer[J]. Int J Nanomed, 2013, 8(1):971.
[63] Kutty R V, Feng S S. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers[J]. Biomaterials, 2013, 34(38):10160.
[64] Wang B L, Gao X, Men K, et al. Treating acute cystitis with biodegradable micelle-encapsulated quercetin[J]. Int J Nanomed, 2012, 7(5):2239.
[65] Kokuryo D, Nakashima S, Ozaki F, et al. Evaluation of thermo-triggered drug release in intramuscular-transplanted tumors using thermosensitive polymer-modified liposomes and MRI[J]. Nanomedicine, 2015, 11(1):229.
[66] Wei X, Senanayake T H, Warren G, et al. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for targeting of CD44-positive and drug-resistant tumors[J]. Bioconjug Chem, 2013, 24(4):658-668.
[67] Yallapu M M, Ebeling M C, Chauhan N, et al. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes[J]. Int J Nanomed, 2011, 6(1):2779.
[68] Yan Y, Wang Y J, Wu J H, et al. Studies on anticancer activity of 17-AAG poly-butylcyanoacrylate nanoparticle[J].J Cap Med Univ, 2015, 36(2):178-184.
[69] Shi F, Cui C Y, Wu J H, et al. Evaluation of anti-tumor activity of docetaxel loaded nanostructured lipid carriers with seal oil[J]. J Cap Med Univ, 2015, 36(2):185-191.
[70] Xing L, Cui C Y, Wang Y J, et al. 6-Mercaptopurine/verapamil-mesoporous silica and reversing multidrug resistance[J]. J Cap Med Univ, 2015, 36(2):161-165.